Newly Public SL Science Reports 35% Revenue Drop, 221% Net Loss Increase for FY2025
Summary
SL Science reported a 35% decrease in net revenue to $2.20 million and a 221% increase in net loss to $(3.82) million for full-year 2025. Gross profit also fell 60%. These significantly negative results follow the company's Nasdaq listing on June 15th and a 20-F filing earlier today that disclosed "going concern" issues. The reported figures provide the financial details behind the "going concern" warning, highlighting substantial operational challenges for the newly public biomedical firm. The company is targeting a Pre-IND meeting and formal IND submission for its CD-19 Armed-T blood cancer program in Q1 2027.
At the time of this announcement, SLBT was trading at $5.61 on NASDAQ in the Life Sciences sector. The 52-week trading range was $3.00 to $14.50. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.